First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Cristiana Sessa(Institute of Oncology Research), Udai Banerji(Institute of Cancer Research), Mikhail Akimov(Novartis (Switzerland)), Cornelia Quadt(Novartis (Switzerland)), Stuart Bailey(Novartis (Switzerland)), Vali Papadimitrakopoulou(Novartis (Switzerland)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Carolyn D. Britten(APLA Health), Sandra Chica(Novartis (Switzerland)), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center), Karen S. Jacks(Novartis (Switzerland)), Cristina Fernandez‐Ibarra(Novartis (Switzerland)), Hong Lü(United States Food and Drug Administration), Tim Pluard(Novartis (Switzerland)), Monica Mita(Novartis (Switzerland)), Thomas A. Samuel(Novartis (Switzerland))
Cited by 160
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
|International Journal of Gynecological Cancer|2015|757
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
|Journal of Biological Chemistry|2005|749